Neumora Therapeutics, Inc. (Nasdaq: NMRA) announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a robust cash position of $182.5 million, which is expected to support operations into the third quarter of 2027. The company reported a net loss of $59.4 million for Q4 2025, slightly higher than the $58.8 million loss in Q4 2024. For the full year, Neumora's net loss was $236.9 million, compared to $243.8 million in 2024. The decrease in losses is attributed to reduced research and development expenses, which totaled $44.7 million for Q4 2025, down from $45.9 million in the same period last year. Neumora's pipeline continues to show promise, particularly with NMRA-511, which demonstrated significant clinical effects in Alzheimer's disease agitation. The company also announced that the KOASTAL-2 and -3 studies were fully enrolled in Q1 2026, with topline data expected in Q2 2026. Additionally, NMRA-898 has been selected as the lead program in the M4 franchise, showing promising results in ongoing Phase 1 studies. Neumora's strategic focus on advancing its pipeline positions it well for future growth and potential market impact.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.